Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03902821 · ClinicalTrials.gov registry record
Reducing Overdose After Release From Incarceration
A clinical trial of Overdose, Drug, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- 65
- Enrollment target
- 1
- Study location
NCT03902821: Completed study of Overdose, Drug, sponsored by Oregon Health and Science University.
NCT03902821 is a study of Overdose, Drug that has completed, run by Oregon Health and Science University. The registered enrollment target is 65 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03902821, a study of Overdose, Drug, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the ROAR project is to evaluate an Oregon Department of Corrections (ODOC) pilot program that combines the use of extended-release naltrexone (XR-NTX) and Certified Recovery Mentors pre-release with linkage to community substance use disorder treatment to prevent fatal and non-fatal opioid overdoses among female adults released from prison.
Primary Outcome
This is a binary outcome indicating a fatal or non-fatal opioid-related overdose event
Conditions Studied
Interventions
- OTHER XR-NTX and Certified Recovery Mentor
Study Locations (1)
Oregon
- Oregon Department of Corrections - Wilsonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2019-06-17 |
| Est. Completion | 2023-11-30 |
What the finished NCT03902821 record still lists
NCT03902821 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 1 condition, with Overdose, Drug appearing as the primary indexed condition, and to 1 intervention - of which XR-NTX and Certified Recovery Mentor is the first listed.
NCT03902821 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03902821 about?
NCT03902821 is a clinical study titled "Reducing Overdose After Release From Incarceration". The primary objective of the ROAR project is to evaluate an Oregon Department of Corrections (ODOC) pilot program that combines the use of extended-release naltrexone (XR-NTX) and Certified Recovery Mentors pre-release with linkage to community substance use disorder treatment to prevent fatal and n...
What is the current status of trial NCT03902821?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2019-06-17. Estimated completion is 2023-11-30.
What conditions does trial NCT03902821 study?
This clinical trial studies the following conditions: Overdose, Drug.
What interventions are being tested in trial NCT03902821?
The interventions under investigation include: XR-NTX and Certified Recovery Mentor (OTHER).
Who is sponsoring clinical trial NCT03902821?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03902821 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI